Date: 2012-10-23
Type of information: Development agreement
Compound: multi-specific Tribody Drug Conjugates (TDCs)
Company: PolyTherics (UK) Biotecnol (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: Tribody molecules are multi-specific antibody products that, from a single molecule, enable the targeting of two or three tumour antigens in the same disease or two or three epitopes on the same tumour target. In vitro and in vivo studies conducted by Biotecnol have demonstrated Tribodies to have strong targeting abilities and high tumour-to-blood ratios, which make them highly suitable for delivering toxic payloads in certain key disease settings.
Disease: cancer
Details: Biotecnol and PolyTherics have entered into a collaboration for the development of multi-specific Tribody Drug Conjugates (TDCs). The companies will combine Biotecnol’s Tribody technology with PolyTherics’ proprietary site-specific linker technologies to attach cytotoxic payloads to various Tribodies for targeted cancer therapy. Biotecnol has a large repertoire of multivalent antibodies, and well-established capabilities in antibody development and antibody engineering, which will be directed towards this collaboration.
PolyTherics’ novel ThioBridge™ linker technology is a superior conjugation technology for creating more stable, less heterogeneous antibody drug conjugates (ADCs) through site-specific linkage and rebridging of disulphide bonds. It has been developed to support the conjugation of a range of therapeutic payloads to antibodies, antibody fragments or scaffolds via specific sites without impacting functional domains. PolyTherics’ ThioBridge™ technology also enables the development of conjugates with improved solubility and a reduced risk of aggregation.
The companies will test the potency of the ThioBridge™ Tribody-drug conjugates in preclinical cancer models. Biotecnol and PolyTherics will jointly seek partners to develop the most promising product candidates that arise from the collaboration.
Financial terms:
Latest news:
